BioStock: Immunicum aiming for new heights within immuno-oncology

Thanks to the merger with DCprime, Swedish immuno-oncology company Immunicum has built a solid foundation for becoming an integrated, international organization with an advanced clinical pipeline.  Following the release of the company’s Q2 report, BioStock reached out to Immunicum’s CEO Erik Manting to get his view on the company’s main goals and what to expect from Immunicum during the rest of 2021. 

 Read the interview with Immunicum's CEO Erik Manting at biostock.se:

https://www.biostock.se/en/2021/09/immunicum-aiming-for-new-heights-within-immuno-oncology/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se